SCHEMBL20258282

SCHEMBL20258282

CC(C)(C)OC(=O)N1C[C@H](NOCc2ccccc2)CC[C@]1(C(=O)O)N1C(=O)C2CC=CCC2C1=O

nearest known ligand 0.36

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
STS P08842 1/20 0.35
USP30 Q70CQ3 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
KMT2A Q03164 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
YAP1 P46937 2/20 0.33
GPR119 Q8TDV5 2/20 0.33
JAK2 O60674 1/20 0.33
JAK1 P23458 1/20 0.33
ALDH1A1 P00352 1/20 0.32
PARP1 P09874 1/20 0.32
KEAP1 Q14145 1/20 0.32
NFE2L2 Q16236 1/20 0.32
KDM4E B2RXH2 1/20 0.32
PKM P14618 1/20 0.32
KLK7 P49862 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17956487 1.00 STS (0.35) STSUSP30SMN1; SMN2KMT2AL3MBTL1
SCHEMBL17956400 0.92 USP30 (0.37) STSUSP30KMT2AL3MBTL1YAP1
SCHEMBL18044440 0.92 USP30 (0.37) STSUSP30KMT2AL3MBTL1YAP1
SCHEMBL20258276 0.92 USP30 (0.37) STSUSP30KMT2AL3MBTL1YAP1
SCHEMBL21847863 0.89 ALDH1A1 (0.36) SMN1; SMN2ALDH1A1
SCHEMBL17956503 0.88 USP30 (0.36) STSUSP30KMT2AL3MBTL1YAP1
SCHEMBL20258290 0.88 USP30 (0.36) STSUSP30KMT2AL3MBTL1YAP1
SCHEMBL20258292 0.87 SMN1; SMN2 (0.37) STSUSP30SMN1; SMN2KMT2AL3MBTL1
SCHEMBL20258281 0.80 JAK2 (0.36) STSUSP30SMN1; SMN2KMT2AL3MBTL1
SCHEMBL19409528 0.80 JAK2 (0.36) STSUSP30SMN1; SMN2KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10000491-B2 Process for producing diazabicyclooctane derivative and intermediate thereof MEIJI SEIKA PHARMA CO., LTD. (JP) 2018-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10000491-B2 Process for producing diazabicyclooctane derivative and intermediate thereof CLCN2, ODC1, KCNN4 STS 3538/4885USP30 3438/4885SMN1; SMN2 4784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.